Personalized treatment for thyroid cancer: current data and new perspectives.

Personalized treatment for thyroid cancer: current data and new perspectives. Minerva Endocrinol. 2020 Nov 19;: Authors: Colombo C, Giancola N, Fugazzola L Abstract More conservative and personalized treatment options have been developed in recent years to face the rising diagnosis of low-risk differentiated thyroid carcinoma (DTC). The present review describes the changes in the direction toward a more risk-adapted management either in the treatment or in the follow-up of DTC. Particular attention is given to the innovations introduced by the latest guidelines for low-risk tumors, starting from the most appropriate extension of surgery up to the post-operative management. The emerging role of active surveillance for lowrisk microcarcinoma is discussed, as well as the development of percutaneous strategies in the setting of malignant thyroid disease. The recent use of approved new systemic target therapies for advanced radioiodine refractory thyroid cancer is reported, together with the description of new compounds in trial. Finally, we provide some considerations to improve the risk evaluation in a pre-surgical setting, especially related to the rising role of genetics, in order to enable better risk-based cancer management and personalized treatment choice. PMID: 33213119 [PubMed - as supplied by publisher]
Source: Minerva Endocrinologica - Category: Endocrinology Tags: Minerva Endocrinol Source Type: research